


Complete listing of all claims, with markings and status identifiers  
(currently amended claims showing deletions by ~~strike through~~ and additions by underlining)

1. (Canceled)

2. (Canceled)

3. (Currently amended) A compound ~~according to claim 2~~ of formula (I),



(I)

wherein

A<sup>7</sup> is L-His, Ura, Paa, Pta, Amp, Tma-His, des-amino-His, or deleted;

A<sup>8</sup> is Ala,  $\beta$ -Ala, Gly, Ser, D-Ala, Aib, Acc, N-Me-Ala, N-Me-D-Ala or N-Me-Gly;

A<sup>9</sup> is Glu, N-Me-Glu or N-Me-Asp;

A<sup>10</sup> is Gly, Acc,  $\beta$ -Ala or Aib;

A<sup>11</sup> is Thr;

A<sup>12</sup> is Phe, Acc, 1Nal, 2Nal, or Aic;

A<sup>13</sup> is Thr;

A<sup>14</sup> is Ser or Aib;

A<sup>15</sup> is Asp;

A<sup>16</sup> is Val, Acc or Aib;

A<sup>17</sup> is Ser;

A<sup>18</sup> is Ser or Lys;

A<sup>19</sup> is Tyr, 1Nal or 2Nal;

A<sup>20</sup> is Leu, Acc or Cha;

A<sup>21</sup> is Glu;

A<sup>22</sup> is Gly, Acc,  $\beta$ -Ala, Glu or Aib;

A<sup>23</sup> is Gln or Glu;

A<sup>24</sup> is Ala, Aib or Acc;

A<sup>25</sup> is Ala, Aib, Acc, Lys, Arg, hArg, Orn, HN-CH((CH<sub>2</sub>)<sub>n</sub>-N(R<sup>10</sup>R<sup>11</sup>))-C(O) or HN-CH((CH<sub>2</sub>)<sub>e</sub>-X<sup>3</sup>)-C(O);

A<sup>26</sup> is Lys, Arg, hArg, Orn, Lys(N<sup>e</sup>-decanoyl), HN-CH((CH<sub>2</sub>)<sub>n</sub>-N(R<sup>10</sup>R<sup>11</sup>))-C(O) or HN-CH((CH<sub>2</sub>)<sub>e</sub>-X<sup>3</sup>)-C(O);

A<sup>27</sup> is Glu, Leu, Aib or Lys;

A<sup>28</sup> is Phe, 1Nal or 2Nal;

A<sup>29</sup> is Ile or Acc;

A<sup>30</sup> is Ala or Aib;

A<sup>31</sup> is Trp, Phe, 1Nal or 2Nal;

A<sup>32</sup> is Leu, Acc or Cha; and

A<sup>33</sup> is Val, Lys or Acc;

A<sup>34</sup> is Lys, Arg, hArg, Orn, HN-CH((CH<sub>2</sub>)<sub>n</sub>-N(R<sup>10</sup>R<sup>11</sup>))-C(O) or HN-CH((CH<sub>2</sub>)<sub>e</sub>-X<sup>3</sup>)-C(O);

A<sup>35</sup> is β-Ala, D-Ala, Gaba, Ava, HN-(CH<sub>2</sub>)<sub>m</sub>-C(O), Aib, Acc, D-Arg or a D-amino acid;

A<sup>36</sup> is L- or D-Arg, D- or L-Lys, or Lys(N<sup>e</sup>-decanoyl) or Lys(N<sup>e</sup>-dodecanoyl) or D- or L-hArg, D- or L-Orn or HN-CH((CH<sub>2</sub>)<sub>n</sub>-N(R<sup>10</sup>R<sup>11</sup>))-C(O), or HN-CH((CH<sub>2</sub>)<sub>e</sub>-X<sup>3</sup>)-C(O);


A<sup>37</sup> is Gly, β-Ala, Gaba, Aib, Acc, Act, Apc, Aun, Ava, Pro, Dhp, Dmt, Pip, L- or

D- Arg, L- or D- Asp or Glu, Lys(N<sup>e</sup>-decanoyl), Lys(N<sup>e</sup>-dodecanoyl), Lys(N<sup>e</sup>-octanoyl), Lys(N<sup>e</sup>-tetradecanoyl), or Ser(O-decanoyl);

A<sup>38</sup> is D- or L- His, L- or D-Ala, Asn, Gln, Ser, Thr, Acc, Ado, Aib, Apc, Act, Arg, Ava, Gly, β-Ala, Gaba, or HN-(CH<sub>2</sub>)<sub>s</sub>-C(O);

A<sup>39</sup> is D- or L- His, L- or D-Ala, Asn, Gln, Ser, Thr, Acc, Ado, Aib, Apc, Act, Arg, Aun, Gly, β-Ala, Gaba, Lys(N<sup>e</sup>-octanoyl), HN-(CH<sub>2</sub>)<sub>s</sub>-C(O), or deleted;

R<sup>1</sup> is OH, NH<sub>2</sub>, (C<sub>1</sub>-C<sub>30</sub>)alkoxy, or NH-X<sup>2</sup>-CH<sub>2</sub>-Z<sup>0</sup>, wherein X<sup>2</sup> is a (C<sub>0</sub>-C<sub>2</sub>), (C<sub>4</sub>-C<sub>9</sub>) or (C<sub>11</sub>-C<sub>19</sub>)hydrocarbon moiety and Z<sup>0</sup> is H, OH, CO<sub>2</sub>H or CONH<sub>2</sub>;

X<sup>3</sup> is   
$$X^4 - \text{N} \begin{array}{c} \diagup \quad \diagdown \\ | \quad | \\ \text{---} \end{array} \text{N} - (\text{CH}_2)_f - \text{CH}_3 \quad - \text{NH} - \text{C}(\text{O}) - \text{CH}_2 - \text{N} \begin{array}{c} \diagup \quad \diagdown \\ | \quad | \\ \text{---} \end{array} \text{N} - (\text{CH}_2)_2 - \text{NH} - \text{C}(\text{O}) - \text{R}^{13}$$

or -C(O)-NHR<sup>12</sup>, wherein X<sup>4</sup> is, independently for each occurrence, -C(O)-, -NH-C(O)- or -CH<sub>2</sub>-, and wherein f is, independently for each occurrence, an integer from 1 to 29 inclusive;

each of R<sup>2</sup> and R<sup>3</sup> is independently selected from the group consisting of H, (C<sub>1</sub>-C<sub>30</sub>)alkyl, (C<sub>2</sub>-C<sub>30</sub>)alkenyl, optionally substituted phenyl(C<sub>1</sub>-C<sub>30</sub>)alkyl, optionally substituted naphthyl(C<sub>1</sub>-C<sub>30</sub>)alkyl, hydroxy(C<sub>1</sub>-C<sub>30</sub>)alkyl, hydroxy(C<sub>2</sub>-C<sub>30</sub>)alkenyl, hydroxyphenyl(C<sub>1</sub>-C<sub>30</sub>)alkyl, and hydroxynaphthyl(C<sub>1</sub>-C<sub>30</sub>)alkyl;

wherein the phenyl group of said optionally substituted phenyl(C<sub>1</sub>-C<sub>30</sub>)alkyl moiety, and said naphthyl group of said optionally substituted naphthyl(C<sub>1</sub>-C<sub>30</sub>)alkyl moiety each is,

independently for each occurrence, substituted with 1 or more substituents selected, independently for each occurrence, from the group consisting of halo, OH, NH<sub>2</sub>, NO<sub>2</sub> and CN;

or one of R<sup>2</sup> and R<sup>3</sup> is  $(\text{CH}_3)_2\text{-N}-\overset{\uparrow}{\text{C}}^+=\text{N}(\text{CH}_3)_2$ , (C<sub>1</sub>-C<sub>30</sub>)acyl, (C<sub>1</sub>-C<sub>30</sub>)alkylsulfonyl, C(O)X<sup>5</sup>,

$\text{Y}(\text{CH}_2)_r\text{-N} \begin{array}{c} \diagup \diagdown \\ \diagdown \diagup \end{array} \text{N}-(\text{CH}_2)_q\text{SO}_2\text{-}$   $\text{Y}(\text{CH}_2)_r\text{-N} \begin{array}{c} \diagup \diagdown \\ \diagdown \diagup \end{array} \text{N}-(\text{CH}_2)_q\text{-CO-}$   
, or ; wherein Y is H, OH or

NH<sub>2</sub>; r is 0 to 4; q is 0 to 4; and X<sup>5</sup> is (C<sub>1</sub>-C<sub>30</sub>)alkyl, (C<sub>2</sub>-C<sub>30</sub>)alkenyl, phenyl(C<sub>1</sub>-C<sub>30</sub>)alkyl, naphthyl(C<sub>1</sub>-C<sub>30</sub>)alkyl, hydroxy(C<sub>1</sub>-C<sub>30</sub>)alkyl, hydroxy(C<sub>2</sub>-C<sub>30</sub>)alkenyl, hydroxyphenyl(C<sub>1</sub>-C<sub>30</sub>)alkyl or hydroxynaphthyl(C<sub>1</sub>-C<sub>30</sub>)alkyl;

X<sup>6</sup>, X<sup>7</sup>, X<sup>8</sup>, X<sup>9</sup>, X<sup>10</sup> for each occurrence is independently selected from the group consisting of H, (C<sub>1</sub>-C<sub>6</sub>)alkyl, OH, OR<sup>4</sup>, NO<sub>2</sub>, CN, and halo;

R<sup>4</sup> is (C<sub>1</sub>-C<sub>30</sub>)alkyl, (C<sub>2</sub>-C<sub>30</sub>)alkenyl, phenyl(C<sub>1</sub>-C<sub>30</sub>)alkyl, naphthyl(C<sub>1</sub>-C<sub>30</sub>)alkyl, hydroxy(C<sub>1</sub>-C<sub>30</sub>)alkyl, hydroxy(C<sub>2</sub>-C<sub>30</sub>)alkenyl, hydroxyphenyl(C<sub>1</sub>-C<sub>30</sub>)alkyl or hydroxynaphthyl(C<sub>1</sub>-C<sub>30</sub>)alkyl;

e is, independently for each occurrence, an integer from 1 to 4 inclusive;

m is, independently for each occurrence, an integer from 5 to 24 inclusive;

s is, independently for each occurrence, an integer from 5 to 10 or from 12 to 20 inclusive;

n is, independently for each occurrence, an integer from 1 to 5, inclusive;

each of R<sup>10</sup> and R<sup>11</sup> is, independently for each occurrence, H, (C<sub>1</sub>-C<sub>30</sub>)alkyl, (C<sub>1</sub>-C<sub>30</sub>)acyl, (C<sub>1</sub>-

$\text{-C(O)-CH}_2\text{-N} \begin{array}{c} \diagup \diagdown \\ \diagdown \diagup \end{array} \text{N}-(\text{CH}_2)_f\text{-CH}_3$   
C<sub>30</sub>)alkylsulfonyl, -C((NH)(NH<sub>2</sub>)) or ; and

R<sup>12</sup> and R<sup>13</sup> each is, independently for each occurrence, (C<sub>1</sub>-C<sub>30</sub>)alkyl;

provided that:

when A<sup>7</sup> is Ura, Paa or Pta, then R<sup>2</sup> and R<sup>3</sup> are deleted;

when R<sup>10</sup> is (C<sub>1</sub>-C<sub>30</sub>)acyl, (C<sub>1</sub>-C<sub>30</sub>)alkylsulfonyl, -C((NH)(NH<sub>2</sub>)) or

$\text{-C(O)-CH}_2\text{-N} \begin{array}{c} \diagup \diagdown \\ \diagdown \diagup \end{array} \text{N}-(\text{CH}_2)_f\text{-CH}_3$   
, then R<sup>11</sup> is H or (C<sub>1</sub>-C<sub>30</sub>)alkyl;

(i) at least one amino acid of a compound of formula (I) is not the same as the native sequence of hGLP-1(7-38 or -39)NH<sub>2</sub> or hGLP-1(7-38 or -39)OH;

(ii) a compound of formula (I) is not an analogue of hGLP-1(7-38 or -39)NH<sub>2</sub> or hGLP-1(7-38, or -39)OH wherein a single position has been substituted by Ala;

(iii) a compound of formula (I) is not (Arg<sup>26,34</sup>, Lys<sup>38</sup>)hGLP-1(7-38)-E, (Lys<sup>26</sup>(N<sup>ε</sup>-alkanoyl))hGLP-1(7-38)-E, (Lys<sup>34</sup>(N<sup>ε</sup>-alkanoyl))hGLP-1(7-38)-E, (Lys<sup>26,34</sup>-bis(N<sup>ε</sup>-alkanoyl))hGLP-1(7-38)-E, (Arg<sup>26</sup>, Lys<sup>34</sup>(N<sup>ε</sup>-alkanoyl))hGLP-1(8-38)-E, (Arg<sup>26,34</sup>, Lys<sup>36</sup>(N<sup>ε</sup>-alkanoyl))hGLP-1(7-38)-E or (Arg<sup>26,34</sup>, Lys<sup>38</sup>(N<sup>ε</sup>-alkanoyl))hGLP-1(7-38)-E, wherein E is -OH or -NH<sub>2</sub>;

(iv) a compound of formula (I) is not Z<sup>1</sup>-hGLP-1(7-38)-OH, Z<sup>1</sup>-hGLP-1(7-38)-NH<sub>2</sub>; wherein Z<sup>1</sup> is selected from the group consisting of:

(a) (Arg<sup>26</sup>), (Arg<sup>34</sup>), (Arg<sup>26,34</sup>), (Lys<sup>36</sup>), (Arg<sup>26</sup>, Lys<sup>36</sup>), (Arg<sup>34</sup>, Lys<sup>36</sup>), (D-Lys<sup>36</sup>), (Arg<sup>36</sup>), (D-Arg<sup>36</sup>), (Arg<sup>26,34</sup>, Lys<sup>36</sup>) or (Arg<sup>26,36</sup>, Lys<sup>34</sup>);

(b) (Asp<sup>21</sup>);

(c) at least one of (Aib<sup>8</sup>), (D-Ala<sup>8</sup>) and (Asp<sup>9</sup>); and

(d) (Tyr<sup>7</sup>), (N-acyl-His<sup>7</sup>), (N-alkyl-His<sup>7</sup>), (N-acyl-D-His<sup>7</sup>) or (N-alkyl-D-His<sup>7</sup>); and


(v) a compound of formula (I) is not a combination of any two of the substitutions listed in groups (a) to (d);

or a pharmaceutically acceptable salt thereof.


4. (Currently amended) A compound according to ~~claim 2~~ claim 3, wherein A<sup>8</sup> is Ala, Gly, Ser, D-Ala, Aib, A6c, A5c, N-Me-Ala, N-Me-D-Ala or N-Me-Gly; A<sup>10</sup> is Gly; A<sup>12</sup> is Phe, 1Nal, 2Nal, A6c or A5c; A<sup>16</sup> is Val, A6c or A5c; A<sup>20</sup> is Leu, A6c, A5c or Cha; A<sup>22</sup> is Gly, β-Ala, Glu or Aib; A<sup>24</sup> is Ala or Aib; A<sup>29</sup> is Ile, A6c or A5c; A<sup>32</sup> is Leu, A6c, A5c or Cha; A<sup>33</sup> is Val, Lys, A6c or A5c; A<sup>35</sup> is Aib, β-Ala, Ado, A6c, A5c, D-Arg or Acc; A<sup>37</sup> is Gly, Aib, β-Ala, D-Ala, Pro, Asp, Aun or D-Asp; A<sup>38</sup> is D- or L- His, Asn, Ser, Apc, Act, Gly, β-Ala or Gaba; and A<sup>39</sup> is Ser, Thr or Aib; or a pharmaceutically acceptable salt thereof.

5. (Original) A compound according to claim 4 or a pharmaceutically acceptable salt thereof, X<sup>4</sup> for each occurrence is -C(O)-; and R<sup>1</sup> is OH or NH<sub>2</sub>; or a pharmaceutically acceptable salt thereof.


6. (Original) A compound according to claim 5 or a pharmaceutically acceptable salt thereof, wherein R<sup>2</sup> is H and R<sup>3</sup> is (C<sub>1</sub>-C<sub>30</sub>)alkyl, (C<sub>2</sub>-C<sub>30</sub>)alkenyl, (C<sub>1</sub>-C<sub>30</sub>)acyl, (C<sub>1</sub>-C<sub>30</sub>)alkylsulfonyl,




or




7. (Original) A compound according to claim 5 or a pharmaceutically acceptable salt thereof, wherein  $\text{R}^{10}$  is  $(\text{C}_1\text{-C}_{30})\text{acyl}$ ,  $(\text{C}_1\text{-C}_{30})\text{alkylsulfonyl}$  or



8. (Original) A compound according to claim 7 or a pharmaceutically acceptable salt thereof, wherein  $\text{R}^{10}$  is  $(\text{C}_4\text{-C}_{20})\text{acyl}$ ,  $(\text{C}_4\text{-C}_{20})\text{alkylsulfonyl}$  or




9. (Currently amended) A compound according to ~~claim 2~~ claim 3, wherein:  
 $\text{A}^8$  is Ala, D-Ala, Aib, A6c, A5c, N-Me-Ala, N-Me-D-Ala or N-Me-Gly;  $\text{A}^{10}$  is Gly;  $\text{A}^{12}$  is Phe, 1Nal, 2Nal, A6c or A5c;  $\text{A}^{16}$  is Val, A6c or A5c;  $\text{A}^{20}$  is Leu, A6c, A5c or Cha;  $\text{A}^{22}$  is Gly,  $\beta$ -Ala, Glu or Aib;  $\text{A}^{24}$  is Ala or Aib;  $\text{A}^{29}$  is Ile, A6c or A5c;  $\text{A}^{32}$  is Leu, A6c, A5c or Cha;  $\text{A}^{33}$  is Val, Lys, A6c or A5c;  $\text{A}^{35}$  is Aib,  $\beta$ -Ala, Ado, A6c, A5c or D-Arg; and  $\text{A}^{37}$  is Gly, Aib,  $\beta$ -Ala, D-Ala, Pro or D-Asp;  $\text{A}^{38}$  is D- or L- His, Asn, Ser, Gly,  $\beta$ -Ala or Gaba; and  $\text{A}^{39}$  is Ser, or deleted;  $\text{X}^4$  for each occurrence is  $-\text{C}(\text{O})-$ ; e for each occurrence is independently 1 or 2;  $\text{R}^1$  is OH or  $\text{NH}_2$ ;  $\text{R}^{10}$  is



$(\text{C}_1\text{-C}_{30})\text{acyl}$ ,  $(\text{C}_1\text{-C}_{30})\text{alkylsulfonyl}$  , and  $\text{R}^{11}$  is H;  
or a pharmaceutically acceptable salt thereof.

10. (Original) A compound according to claim 9, wherein R<sup>10</sup> is (C<sub>4</sub>-C<sub>20</sub>)acyl, (C<sub>4</sub>-



C<sub>20</sub>)alkylsulfonyl or , or a pharmaceutically acceptable salt thereof.

11. (Currently amended) A compound according to ~~claim 2~~ claim 3 wherein said compound is according to the formula:

(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Phe<sup>31</sup>, Pro<sup>37</sup>, Ser<sup>38,39</sup>)hGLP-1(7-39)-NH<sub>2</sub>; (SEQ ID NO:1)

(Aib<sup>8,35,37</sup>, Arg<sup>26,34</sup>, Phe<sup>31</sup>, Asn<sup>38</sup>)hGLP-1(7-38)-NH<sub>2</sub>; (SEQ ID NO:2)

(Aib<sup>8,35,37</sup>, Arg<sup>26,34</sup>, Phe<sup>31</sup>, Ser<sup>38</sup>)hGLP-1(7-38) NH<sub>2</sub>; (SEQ ID NO:3)

(Aib<sup>8,35,37</sup>, Gaba<sup>38</sup>)hGLP-1(7-38) NH<sub>2</sub>; (SEQ ID NO:4)

(Aib<sup>8,35,37</sup>, Arg<sup>26,34</sup>, Phe<sup>31</sup>, His<sup>38</sup>)hGLP-1(7-38) NH<sub>2</sub>; (SEQ ID NO:5)

(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Phe<sup>31</sup>, β-Ala<sup>37</sup>, His<sup>38</sup>)hGLP-1(7-38) NH<sub>2</sub>; (SEQ ID NO:6)

(Aib<sup>8,35,37</sup>, Arg<sup>26,34</sup>, D-His<sup>38</sup>)hGLP-1(7-38) NH<sub>2</sub>; (SEQ ID NO:7)

(Aib<sup>8,35,37</sup>, β-Ala<sup>38</sup>)hGLP-1(7-38) NH<sub>2</sub>; (SEQ ID NO:8)

(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, β-Ala<sup>37</sup>, His<sup>38</sup>)hGLP-1(7-38) NH<sub>2</sub>; (SEQ ID NO:9)

(Aib<sup>8,35,37</sup>, Arg<sup>26,34</sup>, Phe<sup>31</sup>, Gly<sup>38</sup>)hGLP-1(7-38) NH<sub>2</sub>; (SEQ ID NO:10)

(Aib<sup>8,35,37</sup>, Arg<sup>26,34</sup>, Gly<sup>38</sup>)hGLP-1(7-38) NH<sub>2</sub>; (SEQ ID NO:11)

(Aib<sup>8,35,37</sup>, Arg<sup>26,34</sup>, β-Ala<sup>38</sup>)hGLP-1(7-38) NH<sub>2</sub>; (SEQ ID NO:12)

(Aib<sup>8,35,37</sup>, Arg<sup>26,34</sup>, Gaba<sup>38</sup>)hGLP-1(7-38) NH<sub>2</sub>; (SEQ ID NO:13)

(Aib<sup>8,35,37</sup>, Arg<sup>34</sup>, Phe<sup>31</sup>, His<sup>38</sup>)hGLP-1(7-38) NH<sub>2</sub>; (SEQ ID NO:14)

(Aib<sup>8,35,37</sup>, Arg<sup>26,34</sup>, His<sup>38</sup>)hGLP-1(7-38) NH<sub>2</sub>; (SEQ ID NO:15)

(Aib<sup>8,35,37</sup>, Arg<sup>26,34</sup>, Phe<sup>31</sup>, Gaba<sup>38</sup>)hGLP-1(7-38) NH<sub>2</sub>; (SEQ ID NO:16)

(Aib<sup>8,35,37</sup>, Arg<sup>26,34</sup>, Phe<sup>31</sup>, Ava<sup>38</sup>)hGLP-1(7-38) NH<sub>2</sub>; (SEQ ID NO:17)

(Aib<sup>8,35,37</sup>, Arg<sup>26,34</sup>, Ava<sup>38</sup>)hGLP-1(7-38) NH<sub>2</sub>; (SEQ ID NO:18)

(Aib<sup>8,35,37</sup>, Arg<sup>34</sup>, Phe<sup>31</sup>, D-His<sup>38</sup>)hGLP-1(7-38) NH<sub>2</sub>; (SEQ ID NO:19)

(Aib<sup>8,35,37</sup>, Arg<sup>34</sup>, Phe<sup>31</sup>, Gly<sup>38</sup>)hGLP-1(7-38) NH<sub>2</sub>; (SEQ ID NO:20)

(Aib<sup>8,35,37</sup>, Gly<sup>38</sup>)hGLP-1(7-38) NH<sub>2</sub>; (SEQ ID NO:21)

(Aib<sup>8,35,37</sup>, Arg<sup>26,34</sup>, Phe<sup>31</sup>, D-His<sup>38</sup>)hGLP-1(7-38) NH<sub>2</sub>; (SEQ ID NO:22)

(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Phe<sup>31</sup>, β-Ala<sup>37</sup>, D-His<sup>38</sup>)hGLP-1(7-38) NH<sub>2</sub>; (SEQ ID NO:23)

(Aib<sup>8,35,37</sup>, Arg<sup>26,34</sup>, Phe<sup>31</sup>, β-Ala<sup>38</sup>)hGLP-1(7-38) NH<sub>2</sub>; (SEQ ID NO:24)

(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Phe<sup>31</sup>, β-Ala<sup>37,38</sup>)hGLP-1(7-38) NH<sub>2</sub>; (SEQ ID NO:25)

(Aib<sup>8,35,37</sup>, Arg<sup>34</sup>, Phe<sup>31</sup>, β-Ala<sup>38</sup>)hGLP-1(7-38) NH<sub>2</sub>; (SEQ ID NO:26) or  
(Aib<sup>8,35,37</sup>, Arg<sup>34</sup>, Phe<sup>31</sup>, Gaba<sup>38</sup>)hGLP-1(7-38) NH<sub>2</sub>; (SEQ ID NO:27)  
or a pharmaceutically acceptable salt thereof.

12. (Currently amended) A pharmaceutical composition comprising ~~an effective amount~~  
~~of~~ a compound according to ~~claim 2~~ claim 3 or a pharmaceutically acceptable salt thereof and a  
pharmaceutically acceptable carrier or diluent.

13. (Canceled)

14. (Currently amended) A method of treating a disease selected from the group  
consisting of Type I diabetes~~[[,]]~~ and Type II diabetes, ~~obesity, glucagonomas, secretory~~  
~~disorders of the airway, metabolic disorder, arthritis, osteoporosis, central nervous system~~  
~~disease, restenosis, neurodegenerative disease, renal failure, congestive heart failure, nephrotic~~  
~~syndrome, cirrhosis, pulmonary edema, hypertension, treatment of respiratory distress, disorders~~  
~~wherein the reduction of food intake is desired, hypoglycemia and malabsorption syndrome~~  
~~associated with gastrectomy or small bowel resection~~, in a subject in need thereof which  
comprises administering to said subject an effective amount of a compound according to ~~claim 2~~  
claim 11 or a pharmaceutically acceptable salt thereof.

15-27. (Canceled)